Abstract
Epidemiology shows a clear correlation between chronic infection with the hepatitis B virus (HBV) and development of hepatocellular carcinoma (HCC). The potential role of the transactivating hepatitis B virus X protein (HBx) in transformation by HBV is controversial. Here we report that HBx suppresses transformation of primary rat embryo fibroblasts (REFs). Cooperating oncogenes like c-Ha-ras and c-myc transform REF very efficiently but cotransfection with HBx suppressed transformation of REFs down to 5%. Similarly, transfection of HBx together with the cooperating oncogenes Ha-ras and SV40 LTAg or c-Ha-ras and mutant p53 reduced the number of foci to 13%. Comparable results were obtained with HBx in the context of the whole HBV. Suppression of focus formation in REF could be partly relieved by cotransfection of apoptosis inhibitors Bcl-2 or E1B. However, cotransfection of apoptosis inhibitors crmA and p35 did not influence the proapoptotic functions of HBx. Thus, HBx may specifically activate the Bcl-2 sensitive pathway leading to apoptosis. Experiments with 13 HBx linker scanning mutants revealed that the domains necessary for HBx dependent transactivation overlap with the domains needed for the apoptotic/growth arrest functions of HBx.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout









Similar content being viewed by others
References
Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA and Struhl K. (eds). . 1998 Current Protocols in Molecular Biology. John Wiley and Sons, Inc. pp.914–916.
Avantaggiati ML, Natoli G, Balsano C, Chirillo P, Artini M, De Marzio E, Collepardo D and Levrero M. . 1993 Oncogene 8: 1567–1574.
Benn J, Su F, Doria M and Schneider RJ. . 1996 J. Virol. 70: 4978–4985.
Bergametti F, Prigent S, Luber B, Benoit A, Tiollais P, Sarasin A and Transy C. . 1999 Oncogene 18: 2860–2871.
Blum HE, Zhang ZS, Galun E, von Weizsäcker F, Garner B, Liang TJ and Wands JR. . 1992 J. Virol. 66: 1223–1227.
Bréchot C, Jaffredo F, Lagorce D, Gerken G, Meyer zum Büschenfelde K, Papakonstontinou A, Hadziyannis S, Romeo R, Colombo M, Rodes J, Bruix J and Naoumov N. . 1998 J. Hepatol. 29: 173–183.
Chen HS, Kaneko S, Girones R, Anderson RW, Hornbuckle WE, Tennant BC, Cote PJ, Gerin JL, Purcell RH and Miller RH. . 1993 J. Virol. 67: 1218–1226.
Chi S, Kitanaka C, Noguchi K, Mochizuki T, Nagashima Y, Shirouzu M, Fujita H, Yoshida M, Chen W, Asai A, Himeno MSY and Kuchino Y. . 1999 Oncogene 18: 2281.
Chirillo P, Pagano S, Natoli G, Puri PL, Burgio VL, Balsano C and Levrero M. . 1997 Proc. Natl. Acd. Sci. USA 94: 8162–8167.
Cory S and Adams JM. . 1998 Biochim. Biophys. Acta 1377: R25–R44.
Cuende E, Ales-Martinez JE, Liyun D, Gonzalez-Garcia M, Martinez-A C and Nunez G. . 1993 EMBO J. 12: 1555–1560.
Dimri GP, Nakanishi M, Desprez PY, Smith JR and Campisi J. . 1996 Mol. Cell. Biol. 16: 2987–2997.
Doria M, Klein N, Lucito R and Schneider RJ. . 1995 EMBO J. 14: 4747–4757.
el-Deiry WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Burrell M, Hill DE, Healy E, Rees JL, Hamilton SR, Kinzler KW and Vogelstein B. . 1995 Cancer Res. 55: 2910–2919.
Elmore LW, Hancock AR, Chang SF, Wang XW, Chang S, Callahan CP, Geller DA, Will H and Harris CC. . 1997 Proc. Natl. Acad. Sci. USA 94: 14707–14712.
Finlay CA, Hinds PW and Levine AJ. . 1989 Cell 57: 1083–1093.
Gottlob K, Fulco M, Levrero M and Graessmann A. . 1998a J. Biol. Chem. 273: 33347–33353.
Gottlob K, Pagano S, Levrero M and Graessmann A. . 1998b Cancer Res. 58: 3566–3570.
Haas K, Johannes C, Geisen C, Schmidt T, Karsunky H, Blass Kampmann S, Obe G and Möröy T. . 1997 Oncogene 15: 2615–2623.
Höhne M, Schaefer S, Seifer M, Feitelson MA, Paul D and Gerlich WH. . 1990 EMBO J. 9: 1137–1145.
Kairat A, Beerheide W, Zhou G, Tang ZY, Edler L and Schröder CH. . 1999 Intervirology 42: 228–237.
Kekulé AS, Lauer U, Weiss L, Luber B and Hofschneider PH. . 1993 Nature 361: 742–745.
Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW and Vogelstein B. . 1992 Science 256: 827–830.
Khosravi-Far R, Campbell S, Rossman KL and Der CD. . 1998 Adv. Cancer Res. 72: 57–107.
Kim H, Lee H and Yun Y. . 1998 J. Biol. Chem. 273: 381–385.
Klein NP and Schneider RJ. . 1997 Mol. Cell. Biol. 17: 6427–6436.
Land H. . 1995 Methods Enzymol. 254: 37–41.
Land H, Parada LF and Weinberg RA. . 1983 Nature 304: 596–602.
Lara-Pezzi E, Armesilla AL, Majano PL, Redondo JM and Lopez-Cabrera M. . 1998 EMBO J. 17: 7066–7077.
Lee YH and Yun Y. . 1998 J. Biol. Chem. 273: 25510–25515.
Natoli G, Avantaggiati ML, Chirillo P, Puri PL, Ianni A, Balsano C and Levrero M. . 1994 Oncogene 9: 2837–2843.
Oguey D, Dumenco LL, Pierce RH and Fausto N. . 1996 Hepatology 24: 1024–1033.
Olson MF, Paterson HF and Marshall CJ. . 1998 Nature 394: 295–299.
Parker GA, Crook T, Bain M, Sara EA, Farrell PJ and Allday MJ. . 1996 Oncogene 13: 2541–2549.
Peacock JW, Matlashewski GJ and Benchimol S. . 1990 Oncogene 1769–1774.
Peli J, Schröter M, Rudaz C, Hahne M, Meyer C, Reichmann E and Tschopp J. . 1999 EMBO J. 18: 1824–1831.
Ponchel F, Puisieux A, Tabone E, Michot JP, Froschl G, Morel AP, Frebourg T, Fontaniere B, Oberhammer F and Ozturk M. . 1994 Cancer Res. 54: 2064–2068.
Poussin K, Dienes H, Sirma H, Urban S, Beaugrand M, Franco D, Schirmacher P, Brechot C and Paterlini Brechot P. . 1999 Int. J. Cancer 80: 497–505.
Qi X-M, He H, Zhong H and Distelhorst CW. . 1997 EMBO J. 15: 1207–1212.
Rakotomahanina CK, Hilger C, Fink T, Zentgraf H and Schroder CH. . 1994 Oncogene 9: 2613–2621.
Runkel L, Fischer M and Schaller H. . 1993 Virology 197: 529–536.
Schaefer S. . 1999 Advances in Oncology. Vol. 3.: Viruses, Cell Transformation and Cancer. Grand RJA. (ed.). JAI Press: Greenwich.
Schaefer S and Gerlich WH. . 1995 Intervirology 38: 143–154.
Schaefer S, Seifer M, Grimmsmann T, Fink L, Wenderhold S, Höhne MW and Gerlich WH. . 1998 J. Gen. Virol. 79: 767–777.
Schlüter V, Meyer M, Hofschneider PH, Koshy R and Caselmann WH. . 1994 Oncogene 9: 3335–3344.
Seeger C, Baldwin B and Tennant BC. . 1989 J. Virol. 63: 4665–4669.
Seifer M, Heermann KH and Gerlich WH. . 1990a Virology 179: 287–299.
Seifer M, Heermann KH and Gerlich WH. . 1990b Virology 179: 300–311.
Seifer M, Höhne M, Schaefer S and Gerlich WH. . 1991a J. Hepatol. 13: S61–S65.
Seifer M, Höhne M Schaefer S and Gerlich WH. . 1991b Viral Hepatitis-1990. Hollinger F, Lemon S and Margolis H. (eds). Williams and Wilkins: New York pp. 586–588.
Shirakata Y, Kawada M, Fujiki Y, Sano H, Oda M, Yaginuma K, Kobayashi M and Koike K. . 1989 Jpn. J. Cancer Res. 80: 617–621.
Sirma H, Giannini C, Poussin K, Paterlini P, Kremsdorf D and Brechot C. . 1999 Oncogene 18: 4848–4859.
Spandau DF and Lee CH. . 1988 J. Virol. 62: 427–434.
Su F and Schneider RJ. . 1997 Proc. Natl. Acad. Sci. USA 94: 8744–8749.
Susin SA, Zamzami N, Castedo M, Daugas E, Wang HG, Geley S, Fassy F, Reed JC and Kroemer G. . 1997 J. Exp. Med. 186: 25–37.
Tarn C, Bilodeau ML, Hullinger RL and Andrisani OM. . 1999 J. Biol. Chem. 274: 2327–2336.
Terradillos O, Pollicino T, Lecoeur H, Tripodi M, Gougeon ML, Tiollais P and Buendia MA. . 1998 Oncogene 17: 2115–2123.
Twu JS, Lai MY, Chen DS and Robinson WS. . 1993 Virology 192: 346–350.
Wang XW, Gibson MK, Vermeulen W, Yeh H, Forrester K, Stürzbecher HW, Hoeijmakers JH and Harris CC. . 1995 Cancer Res. 55: 6012–6016.
White E, Cipriani R, Sabbatini P and Denton A. . 1991 J. Virol. 65: 2968–2978.
Yen TSB. . 1996 J. Biomed. Sci. 3: 20–30.
Zoulim F, Saputelli J and Seeger C. . 1994 J. Virol. 68: 2026–2030.
Acknowledgements
This work was supported in parts by grant 01 KI 9552 of the Bundesministerium für Forschung und Technologie and grant 01 KI 98589 of the Bundesministerium für Bildung und Forschung to S Schaefer and WH Gerlich. This work was performed in partial fulfilment of the requirements for the Ph.D. thesis of R Schuster.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schuster, R., Gerlich, W. & Schaefer, S. Induction of apoptosis by the transactivating domains of the hepatitis B virus X gene leads to suppression of oncogenic transformation of primary rat embryo fibroblasts. Oncogene 19, 1173–1180 (2000). https://doi.org/10.1038/sj.onc.1203417
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.onc.1203417
Keywords
This article is cited by
-
Avian Reovirus activates a novel proapoptotic signal by linking Src to p53
Apoptosis (2006)
-
Potential oncogene activity of the woodchuck hepatitis post-transcriptional regulatory element (WPRE)
Gene Therapy (2005)
-
Conserved transactivating and pro-apoptotic functions of hepadnaviral X protein in ortho- and avihepadnaviruses
Oncogene (2002)
-
The hepatitis B virus X protein abrogates Bcl-2-mediated protection against Fas apoptosis in the liver
Oncogene (2002)
-
Activated ras oncogene collaborates with HBx gene of hepatitis B virus to transform cells by suppressing HBx-mediated apoptosis
Oncogene (2001)